- Home
- ARGX vs HLN Comparison
ARGX vs HLN Comparison
Compare ARGX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- HLN
- Stock Information
- Founded
- ARGX 2008
- HLN 2022
- Country
- ARGX Netherlands
- HLN United Kingdom
- Employees
- ARGX N/A
- HLN N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- HLN Package Goods/Cosmetics
- Sector
- ARGX Health Care
- HLN Consumer Discretionary
- Exchange
- ARGX Nasdaq
- HLN Nasdaq
- Market Cap
- ARGX 40.4B
- HLN 43.3B
- IPO Year
- ARGX 2017
- HLN N/A
- Fundamental
- Price
- ARGX $644.48
- HLN $10.08
- Analyst Decision
- ARGX Strong Buy
- HLN Strong Buy
- Analyst Count
- ARGX 20
- HLN 2
- Target Price
- ARGX $653.11
- HLN $10.48
- AVG Volume (30 Days)
- ARGX 225.0K
- HLN 9.3M
- Earning Date
- ARGX 02-27-2025
- HLN 03-07-2025
- Dividend Yield
- ARGX N/A
- HLN 1.57%
- EPS Growth
- ARGX N/A
- HLN N/A
- EPS
- ARGX N/A
- HLN 0.18
- Revenue
- ARGX $1,908,659,000.00
- HLN $15,065,004,686.00
- Revenue This Year
- ARGX $73.18
- HLN $2.44
- Revenue Next Year
- ARGX $55.26
- HLN $2.88
- P/E Ratio
- ARGX N/A
- HLN $27.27
- Revenue Growth
- ARGX 85.56
- HLN N/A
- 52 Week Low
- ARGX $349.86
- HLN $7.89
- 52 Week High
- ARGX $678.21
- HLN $10.80
- Technical
- Relative Strength Index (RSI)
- ARGX 49.33
- HLN 65.11
- Support Level
- ARGX $637.15
- HLN $9.86
- Resistance Level
- ARGX $652.23
- HLN $10.06
- Average True Range (ATR)
- ARGX 12.63
- HLN 0.11
- MACD
- ARGX -1.94
- HLN 0.04
- Stochastic Oscillator
- ARGX 30.64
- HLN 97.97
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.